Limits...
Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.

Duan C, Liu X, Liang S, Yang Z, Xia M, Wang L, Chen S, Yu L - J. Cell. Mol. Med. (2014)

Bottom Line: The mechanism of OLFM4 in tumuorigenesis is elusive.Down-regulation of OLFM4 was associated with decreased cumulative survival rate of patients with endometrioid adenocarcinoma.Our data suggested that impairment of ERα signal-mediated OLFM4 expression promoted the malignant progression of endometrioid adenocarcinoma, which may have significance for the therapy of this carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, The First Affiliated Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China.

Show MeSH

Related in: MedlinePlus

Olfactomedin 4 (OLFM4), oestrogen receptor-α (ERα) and progesterone receptor (PR) mRNA level in endometrial tissues measured by real-time RT-PCR. (A) OLFM4 mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (B) OLFM4 mRNA level in well-, moderately- and poorly-differentiated endometrioid adenocarcinomas. (C) ERα mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (D) PR mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. For multiple comparisons between groups the significance level was adjusted to 0.05/3 = 0.017. #P < 0.017, **P < 0.001. NE: normal endometrium; EH: endometrial hyperplasia; EAC: endometrioid adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4119392&req=5

fig02: Olfactomedin 4 (OLFM4), oestrogen receptor-α (ERα) and progesterone receptor (PR) mRNA level in endometrial tissues measured by real-time RT-PCR. (A) OLFM4 mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (B) OLFM4 mRNA level in well-, moderately- and poorly-differentiated endometrioid adenocarcinomas. (C) ERα mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (D) PR mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. For multiple comparisons between groups the significance level was adjusted to 0.05/3 = 0.017. #P < 0.017, **P < 0.001. NE: normal endometrium; EH: endometrial hyperplasia; EAC: endometrioid adenocarcinoma.

Mentions: To confirm the in silico analysis, we assessed the expression of OLFM4 in normal endometrium, precancerous endometrial tissue and endometrial cancer using IHC. Olfactomedin 4 proteins were stained in the cytoplasm of glandular cells (Fig. 1). The rates of OLFM4 high-expression in normal endometrium, endometrial hyperplasia without or with atypia, and endometrioid adenocarcinoma were 43.3, 60.0, 66.7 and 68.0%, respectively (Table S4). The OLFM4 expression level in endometrioid adenocarcinoma was significantly higher than in normal endometrium (P = 0.008), indicating that OLFM4 expression is up-regulated in endometrial carcinogenesis. Similar to what was observed with IHC, the OLFM4 mRNA level detected by real-time PCR in endometrial hyperplasia and endometrioid adenocarcinomas was higher than that in normal endometrium (P < 0.017, Fig. 2A).


Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.

Duan C, Liu X, Liang S, Yang Z, Xia M, Wang L, Chen S, Yu L - J. Cell. Mol. Med. (2014)

Olfactomedin 4 (OLFM4), oestrogen receptor-α (ERα) and progesterone receptor (PR) mRNA level in endometrial tissues measured by real-time RT-PCR. (A) OLFM4 mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (B) OLFM4 mRNA level in well-, moderately- and poorly-differentiated endometrioid adenocarcinomas. (C) ERα mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (D) PR mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. For multiple comparisons between groups the significance level was adjusted to 0.05/3 = 0.017. #P < 0.017, **P < 0.001. NE: normal endometrium; EH: endometrial hyperplasia; EAC: endometrioid adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4119392&req=5

fig02: Olfactomedin 4 (OLFM4), oestrogen receptor-α (ERα) and progesterone receptor (PR) mRNA level in endometrial tissues measured by real-time RT-PCR. (A) OLFM4 mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (B) OLFM4 mRNA level in well-, moderately- and poorly-differentiated endometrioid adenocarcinomas. (C) ERα mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. (D) PR mRNA level in normal endometrium, endometrial hyperplasia and endometrioid adenocarcinoma. For multiple comparisons between groups the significance level was adjusted to 0.05/3 = 0.017. #P < 0.017, **P < 0.001. NE: normal endometrium; EH: endometrial hyperplasia; EAC: endometrioid adenocarcinoma.
Mentions: To confirm the in silico analysis, we assessed the expression of OLFM4 in normal endometrium, precancerous endometrial tissue and endometrial cancer using IHC. Olfactomedin 4 proteins were stained in the cytoplasm of glandular cells (Fig. 1). The rates of OLFM4 high-expression in normal endometrium, endometrial hyperplasia without or with atypia, and endometrioid adenocarcinoma were 43.3, 60.0, 66.7 and 68.0%, respectively (Table S4). The OLFM4 expression level in endometrioid adenocarcinoma was significantly higher than in normal endometrium (P = 0.008), indicating that OLFM4 expression is up-regulated in endometrial carcinogenesis. Similar to what was observed with IHC, the OLFM4 mRNA level detected by real-time PCR in endometrial hyperplasia and endometrioid adenocarcinomas was higher than that in normal endometrium (P < 0.017, Fig. 2A).

Bottom Line: The mechanism of OLFM4 in tumuorigenesis is elusive.Down-regulation of OLFM4 was associated with decreased cumulative survival rate of patients with endometrioid adenocarcinoma.Our data suggested that impairment of ERα signal-mediated OLFM4 expression promoted the malignant progression of endometrioid adenocarcinoma, which may have significance for the therapy of this carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, The First Affiliated Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China.

Show MeSH
Related in: MedlinePlus